Literature DB >> 8432027

c-myc oncogene expression in estrogen-dependent and -independent breast cancer.

R P Shiu1, P H Watson, D Dubik.   

Abstract

We demonstrate that c-myc gene expression is essential for growth of breast cancer cells. It also plays an important role in the progression of human breast cancer. c-myc gene amplification may be important for cancer cell invasion, but perhaps not essential for nodal metastasis. We also provide compelling evidence that the c-myc oncogene is an estrogen target gene in hormone-responsive breast cancer. Hormonal progression of breast cancer could be brought about by the enhanced expression of the c-myc gene, with gene amplification and enhanced c-myc mRNA stability being two major mechanisms involved.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8432027

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  16 in total

1.  Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors.

Authors:  Karina A Galoian; Thomas H Temple; Armen Galoyan
Journal:  Tumour Biol       Date:  2011-04-15

2.  Anticancer mechanisms of Strobilanthes crispa Blume hexane extract on liver and breast cancer cell lines.

Authors:  Rhun Yian Koh; Foong Ping Lim; Leslie Siing Yie Ling; Catherine Pei Ling Ng; Siew Foong Liew; Mei Yeng Yew; Yee Lian Tiong; Anna Pick Kiong Ling; Soi Moi Chye; Khuen Yen Ng
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

3.  Amplifications of oncogene erbB-2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction.

Authors:  G Deng; M Yu; L C Chen; D Moore; W Kurisu; A Kallioniemi; F M Waldman; C Collins; H S Smith
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776.

Authors:  Yung-Luen Yu; Ruey-Hwang Chou; Chia-Han Wu; Ying-Nai Wang; Wei-Jung Chang; Yen-Ju Tseng; Wei-Chao Chang; Chien-Chen Lai; Hong-Jen Lee; Longfei Huo; Chung-Hsuan Chen; Mien-Chie Hung
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

Review 5.  c-Myc oncoprotein: a dual pathogenic role in neoplasia and cardiovascular diseases?

Authors:  Claudio Napoli; Lilach O Lerman; Filomena de Nigris; Vincenzo Sica
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

6.  SRC Increases MYC mRNA Expression in Estrogen Receptor-Positive Breast Cancer via mRNA Stabilization and Inhibition of p53 Function.

Authors:  Christopher Abdullah; Hasan Korkaya; Shinji Iizuka; Sara A Courtneidge
Journal:  Mol Cell Biol       Date:  2018-02-27       Impact factor: 4.272

7.  Combined analysis of copy number alterations by single-nucleotide polymorphism array and MYC status in non-metastatic breast cancer patients: comparison according to the circulating tumor cell status.

Authors:  R Nadal; M Salido; L Nonell; M Rodríguez-Rivera; E Puigdecanet; J L Garcia-Puche; M Macià; J M Corominas; M J Serrano; J A Lorente; F Solé
Journal:  Tumour Biol       Date:  2014-10-07

8.  Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.

Authors:  K I Bland; M M Konstadoulakis; M P Vezeridis; H J Wanebo
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

9.  Tumor Suppressor Effect of RBMS3 in Breast Cancer.

Authors:  Chunyang Wang; Yidan Wu; Yunqi Liu; Fushun Pan; Huijuan Zeng; Xiaoxi Li; Liang Yu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

10.  Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.

Authors:  Almudena Bosch; Silvina P Bertran; Yongke Lu; Avalon Garcia; Alexis M Jones; Marcia I Dawson; Eduardo F Farias
Journal:  Breast Cancer Res       Date:  2012-08-24       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.